![](/img/cover-not-exists.png)
5.28 Combining Fludarabine and Rituximab With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia: The REVLIRIT CLL5 AGMT Phase 1/2 Study—Results from Clinical and Exploratory Analyses of Induction
A. Egle, M. Steurer, F. Gassner, R. Geisberger, T. Melchardt, L. Weiss, M. Fridrik, J. Thaler, A. Lang, R. GreilVolume:
11
Year:
2011
Language:
english
DOI:
10.1016/j.clml.2011.09.182
File:
PDF, 89 KB
english, 2011